David Smith

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

IntegenX, Inc. develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. The firm platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics and biodefense applications. The company was founded by Stevan Jovanovich, Dennis W. Harris, Richard A. Mathies in 2003 and is headquartered in Pleasanton, CA.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

Monterey Innovation Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2020 and is headquartered in New York, NY.

Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.

Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan.